Neither Flexeril (cyclobenzaprine) nor methocarbamol is clearly superior to the other for acute muscle spasm
Both skeletal muscle relaxants demonstrate similar efficacy for acute musculoskeletal pain, but neither is more effective than placebo when combined with NSAIDs, and both carry significant risks of sedation and other adverse effects that may outweigh any marginal benefits. 1, 2, 3
The Evidence Against Both Agents
The most recent high-quality evidence from 2022 analyzed data from four randomized studies comparing seven different skeletal muscle relaxants (SMRs) in emergency department patients with acute low back pain. This study found no statistically significant differences between cyclobenzaprine, methocarbamol, and placebo when all patients also received NSAIDs 3. The mean improvement in disability scores was 10.1 for cyclobenzaprine, 8.1 for methocarbamol, and 10.5 for placebo—essentially equivalent outcomes. Notably, cyclobenzaprine caused significantly more adverse effects than placebo 3.
Multiple guidelines consistently emphasize that these drugs do not actually relax skeletal muscle despite their classification 1, 2. Their effects are nonspecific and related to sedative properties rather than true muscle relaxation 2, 4.
Key Safety Concerns
Cyclobenzaprine (Flexeril)
- Structurally identical to tricyclic antidepressants, particularly amitriptyline 2
- Causes significant anticholinergic effects: confusion, drowsiness, constipation, urinary retention, dry mouth 5
- Can interact dangerously with sedatives and anesthetic agents 5
- Withdrawal symptoms (malaise, nausea, headache) occur after long-term use 5
- Listed in the 2019 Beers Criteria as potentially inappropriate for older adults 6
Methocarbamol
- Causes drowsiness, dizziness, bradycardia, and hypotension 5
- Elimination significantly impaired in liver and kidney disease 5
- Interferes with pyridostigmine and contraindicated in myasthenia gravis 5
- FDA label explicitly states it "does not directly relax tense skeletal muscles" 4
Clinical Recommendation Algorithm
For acute muscle spasm in otherwise healthy adults:
First-line: NSAIDs or acetaminophen alone 7, 8
- These provide equivalent or superior pain relief without the sedation risk
If inadequate response after 48-72 hours:
- Consider adding a short course (≤1 week) of either agent if sedation is acceptable
- Choose methocarbamol if: Patient needs to remain alert, has anticholinergic sensitivity, or takes other medications with anticholinergic properties
- Choose cyclobenzaprine if: Patient has concurrent insomnia from muscle spasms 9
Maximum duration: 2-3 weeks only 10
Avoid entirely if:
Critical Pitfalls to Avoid
Do not prescribe these medications believing they treat muscle spasm. They are sedatives with nonspecific effects 2. If true muscle spasm is suspected, consider baclofen or benzodiazepines instead, though these carry their own significant risks 2.
Do not use for chronic pain. A 2024 systematic review found SMRs ineffective for long-term use in fibromyalgia, low back pain, and headaches 11. The 2020 geriatrics guideline explicitly states these drugs "have no evidence of efficacy in chronic pain" 1.
Warn patients about sedation. Both drugs consistently cause drowsiness and dizziness, increasing fall risk, particularly in older adults 1, 2, 3, 12. The relative risk of CNS adverse events is 2.04 compared to placebo 12.
Bottom Line
Since neither agent demonstrates superiority and both lack efficacy beyond placebo when combined with NSAIDs 3, the most evidence-based approach is to avoid both medications entirely and rely on NSAIDs or acetaminophen alone 7, 8. If you must choose one, methocarbamol has a slightly more favorable side effect profile with less anticholinergic burden 13, 9, though cyclobenzaprine has been studied more extensively 9, 14.